Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489119 | 0.80 | CYP2A6 (0.54) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL1344485 | 0.80 | CYP2A6 (0.54) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL29489123 | 0.78 | CYP2A6 (0.52) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL1341822 | 0.78 | CYP2A6 (0.52) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL2005605 | 0.77 | — | — | |
| SCHEMBL13074509 | 0.75 | CYP2A6 (0.50) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL13037656 | 0.73 | CA2 (0.55) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL29375458 | 0.73 | CYP2A6 (0.50) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| SCHEMBL22137620 | 0.73 | CYP2A6 (0.50) | IMPDH2IMPDH1CYP2A6CA1CA2 | |
| Water SCHEMBL1898776 | 0.71 | CA1 (0.59) | IMPDH2IMPDH1CYP2A6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089963-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-11-09 | — | — | EP | claimed |
| WO-2015066241-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | claimed |
| EP-2855456-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-04-08 | — | — | EP | claimed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | claimed |
| CN-114072398-B | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3971180-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| CN-114072398-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020224396-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | 上海仕谱生物科技有限公司 | 2020-11-12 | — | — | WO | disclosed |
| CN-111909138-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-3458451-A1 | TRPV4 ANTAGONIST | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-20180093951-A1 | PESTICIDALLY ACTIVE CARBAMOYLATED AND THIOCARBAMOYLATED OXIME DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-04-05 | — | — | US | disclosed |
| WO-2017199199-A1 | TRPV4 ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | WO | disclosed |
| EP-3089963-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015066241-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| EP-2855456-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2057143-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027542-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093951-A1 | PESTICIDALLY ACTIVE CARBAMOYLATED AND THIOCARBAMOYLATED OXIME DERIVATIVES | ACHE, DDT, BCHE | IMPDH2 1172/4885IMPDH1 761/4885CYP2A6 94/4885 |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | TDO2, TFPI, PPIG | IMPDH2 514/4885IMPDH1 446/4885CYP2A6 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.